8C63

Crystal structure of arsenoplatin-1/B-DNA adduct obtained upon 4 h of soaking

Summary for 8C63

• Entry DOI: 10.2210/pdb8c63/pdb
• Related: 8C62 8C64
• Descriptor: DNA (5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3'), PLATINUM (II) ION, MAGNESIUM ION, ... (5 entities in total)
• Functional Keywords: duplex, b-dna, arsenoplatin-1, anticancer agent, metallodrug, dna
• Biological source: synthetic construct
• Total number of polymer chains: 2
• Total formula weight: 7964.28

Authors

Troisi, R.,Tito, G.,Ferraro, G.,Sica, F.,Merlino, A. (deposition date: 2023-01-11, release date: 2024-01-31, Last modification date: 2024-02-28)

Primary citation

Troisi, R.,Tito, G.,Ferraro, G.,Sica, F.,Massai, L.,Geri, A.,Cirri, D.,Messori, L.,Merlino, A.
On the mechanism of action of arsenoplatins: arsenoplatin-1 binding to a B-DNA dodecamer.
Dalton Trans, 53:3476-3483, 2024

PubMed Abstract: The reaction of Pt-based anticancer agents with arsenic trioxide affords robust complexes known as arsenoplatins. The prototype of this family of anticancer compounds is arsenoplatin-1 (AP-1) that contains an As(OH) fragment linked to a Pt(II) moiety derived from cisplatin. Crystallographic and spectrometric studies of AP-1 binding to a B-DNA double helix dodecamer are presented here, in comparison with cisplatin and transplatin. Results reveal that AP-1, cisplatin and transplatin react differently with the DNA model system. Notably, in the AP-1/DNA systems, the Pt-As bond can break down with time and As-containing fragments can be released. These results have implications for the understanding of the mechanism of action of arsenoplatins.

PubMed: 38270175
DOI: 10.1039/d3dt04302a

Experimental method

X-RAY DIFFRACTION (1.52 Å)